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Abstract Rupture of a vulnerable atherosclerotic plaque of
the carotid artery is an important underlying cause of clinical
ischemic events, such as stroke. Abundant microvasculature
has been identified as an important aspect contributing to
plaque vulnerability. Plaque microvasculature can be studied
non-invasively with dynamic contrast-enhanced (DCE-)MRI
in animals and patients. In recent years, several DCE-MRI
studies have been published evaluating the association be-
tween microvasculature and other key features of plaque vul-
nerability (e.g., inflammation and intraplaque hemorrhage), as
well as the effects of novel therapeutic interventions. The
present paper reviews this literature, focusing on DCE-MRI
methods of acquisition and analysis of atherosclerotic plaques,
the current state and future potential of DCE-MRI in the eval-
uation of plaque microvasculature in clinical and preclinical
settings.
Keywords Atherosclerosis . Dynamic contrast-enhanced
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Introduction
Rupture of a vulnerable atherosclerotic plaque is an important
underlying cause of clinical ischemic events, such as stroke [1].
Therefore, visualization of vulnerable plaques may aid in the
identification of patients who have an increased risk for a clin-
ical event. Inflammatory cells play an important role during the
development and progression of atherosclerosis [2]. Within
atherosclerotic plaques, activated macrophages have a high
metabolic rate, inducing hypoxia which stimulates the forma-
tion of newmicrovessels originating from the outer layer of the
vessel wall, the adventitia [3, 4]. These newly formed
microvessels generally have impaired endothelial integrity,
which can lead to extravasation of inflammatory cells and
erythrocytes from the microvessel lumen into plaque tissue
[4]. Extravasation of erythrocytes is generally considered as
an important contributing factor to intraplaque hemorrhage
(IPH) [5]. Because lipids constitute 40 % of the erythrocyte
membrane [5], extravasation of erythrocytes leads to increased
cholesterol deposition in the plaque tissue, which in turn stim-
ulates further recruitment of inflammatory cells. All the above
biological events, especially leaky plaque microvasculature,
are considered key features in plaque destabilization [6].
The microvasculature in plaques are very small (up to
∼100 μm in diameter) but can be studied non-invasively by
several imaging modalities, including contrast-enhanced ul-
trasound (CEUS) [7, 8], positron emission tomography
(PET) [9–11], and dynamic contrast-enhanced magnetic reso-
nance imaging (DCE-MRI) [12]. MRI is a well-established
imaging modality that can be used to visualize the main
plaque components: areas of IPH, the lipid-rich necrotic core,
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and fibrous cap status [13–15]. Early studies developed MRI
for the detection of morphological and chemical components
by studying specimen from surgery (carotid endarterectomy
(CEA)). These ex vivo specimens were advantageous for test-
ing and developing MRI sequences, but the lack of blood
precludes studying of the dynamics from DCE [16, 17].
In recent years, a number of studies have applied DCE-
MRI to study atherosclerotic plaque microvasculature. The
present paper reviews the current state and future potential
of DCE-MRI in the evaluation of plaque microvasculature
with applications in animals and patients. First, because the
methods of DCE-MRI are now well-developed and widely
applied but are not familiar to a general audience, we begin
with principles and acquisition methods of DCE-MRI and
methods for (semi)quantitative analysis of DCE-MRI data.
Second, an overview is given of publications on DCE-MRI
of plaque microvasculature (Table 1) used to study one of the
following aspects: (1) associations between plaque microvas-
culature and other plaque features, (2) longitudinal changes in
plaque microvasculature, (3) comparison of different animal
groups and human subjects with a different cardiovascular risk
profile, and (4) evaluation of therapy response. Finally, future
challenges and potential for DCE-MRI to study plaque micro-
vasculature will be discussed.
DCE-MRI Methods to Study Plaque
Microvasculature
Principles of DCE-MRI
All DCE-MRI experiments require serial acquisition of MR
images acquired in a brief time interval to study atherosclerot-
ic plaque microvasculature (Fig. 1). After acquisition of ana-
tomical references (Fig. 1a), the first images of the series,
acquired before contrast injection, are used to determine base-
line signal intensity of the atherosclerotic plaque tissue. Bolus
injection of a low molecular weight non-specific Gadolinium-
based contrast medium follows, and image acquisition is con-
tinued for several minutes. During this period, the bolus of
contrast medium will be distributed, resulting in signal en-
hancement of the blood vessel lumen, vessel wall due to leak-
age of the contrast medium through damaged endothelial, and
other tissues, such as skeletal muscle (Fig. 1b). In this image,
the vessel lumen (circle) appears bright. A ring of enhance-
ment in the outer (adventitial layer) part of the vessel wall
(indicated by white arrows) can be clearly observed. The sig-
nal enhancement in the vessel wall depends on flow, micro-
vascular density, the ability of the contrast medium to leak
from the microvasculature into the extravascular extracellular
space, and reflux. After analysis of the DCE-MR images,
parametric maps (Fig. 1c) of the resulting parameter can be
generated, indicating local leaky plaque microvasculature. In
DCE-MRI studies of atherosclerosis to date, linear or cyclic
Gadolinium-based contrast media have been used.
DCE-MRI studies of brain and tumor perfusion mostly use a
contrast medium injection rate of 2 ml/s (typically 0.1 mmol/
kg). Such fast injection rates result in quick passage of the bolus
through the vessel and a high-contrast medium peak concentra-
tion, necessitating a higher temporal resolution for MR acqui-
sition and compromising spatial resolution. For the evaluation
of carotid atherosclerosis using DCE-MRI, however, high spa-
tial resolution is required for accurate visualization of the vessel
wall. Therefore, some DCE-MRI studies [24, 39] have used a
slower injection rate of 0.5 ml/s in plaque imaging. Previous
research has shown that a high injection rate is most beneficial
for high Ktrans values (>0.2 min−1) [48]. Typically, within the
atherosclerotic lesion, mean Ktrans values below 0.15 are report-
ed [24], and therefore, a lower injection rate may be applied.
Signal enhancement-time curves of DCE-MR images can
be analyzed voxelwise or using a region-of-interest.
Especially in the voxelwise analysis, movement of the subject
during acquisition of the different DCE-MRI sequence time
frames may pose a problem. A solution is to manually shift
individual time frames to correctly align the images, or alter-
natively, to use post-processing methods for automated move-
ment correction and noise reduction [20, 22].
Pulse Sequences for DCE-MRI of Plaque
Microvasculature
Currently, two main categories of pulse sequences for DCE-
MRI of atherosclerotic plaque microvasculature are
employed: Bbright blood^ or Bblack blood^. Black blood im-
aging facilitates improved delineation of the inner vessel wall,
whereas bright blood imaging enables to determine the CM
concentration in the vessel lumen for each patient individually.
Because the luminal CM concentration cannot be quantified
accurately, quantitative analysis of black blood DCE-MRI
with pharmacokinetic models can only be performed using a
reference region model [49] or previously determined gener-
alized input functions [50]. Recently, dedicated imaging
methods have been proposed combining bright and black
blood images in an interleaved fashion, allowing improved
delineation of the vessel wall from black blood images as well
as extraction of vascular input function based on lumen signal
intensity from bright blood images [25, 28••].
A compromise between the desired spatial and the required
temporal resolution must be made regardless of the imaging
method used. Current studies (both in rabbits and patients)
employed an in-plane spatial acquisition resolution of approx-
imately 0.5 × 0.5 mm2. The preclinical rabbit studies have
employed a temporal resolution of 5 s for 2D acquisition tech-
niques and lower temporal resolution (30 s) for 3D techniques.
In patient studies, the temporal resolution ranges from 15 to
30 s per time frame.
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Table 1 Overview of DCE-MRI studies of atherosclerotic plaque
microvasculature. Overview of studies investigating the atherosclerotic
plaque microvasculature using dynamic contrast-enhancedMRI: subjects
(human or rabbits), analysis method (quantitative or semi-quantitative),
main study purpose, and study outcome are shown
Reference Subjects Main study purpose Main study outcome
Chen et al. [18] Patients with CVD
(AIM-HIGH Trial [19]
Scan-rescan reproducibility Moderate reproducibility for Ktrans (Patlak) with a
25 % coefficient of variation. To limit dropout,
intensive operator training, optimized imaging,
and quality control is required
Kerwin et al. [20] CEA patients Method development Development of a motion correcting and
noise reducing algorithm for the analysis
of DCE-MRI of carotid arteries
Kerwin et al. [21] Patients with a carotid
lesion≥AHA type IV
Method comparison Quantitative enhancement characteristics,
such as Ktrans (Patlak), depend on the used
contrast medium (gadobenate dimeglumine
vs gadodiamide)
Ramachandran et al. [22] Humans with CVD risk Method development Development of a registration method for
alignment of different time frames of DCE-
MRI of carotid arteries
Chen et al. [23] Humans with advanced
carotid disease
Method development Extended graphical model exhibits a reduced
bias in Ktrans estimation compared to the
Patlak model
Van Hoof et al. [24] Symptomatic patients
(30–99 % carotid stenosis)
Method comparison Comparison between phase- and magnitude-
based vascular input functions and resulting
effect on pharmacokinetic parameters. No
signal saturation due to blood flow for phase-
based determined vascular input function
Calcagno et al. [25] Humans with CVD risk Method development Demonstration of feasibility of simultaneous
VIF and vessel wall imaging (extended Tofts)
Wan et al [26] NZW Rabbita,b Method development Spatio-temporal texture based features (like AUC)
are able to distinguish between vulnerable and
stable plaques.
Calcagno et al. [27] NZW Rabbitc Method comparison Excellent reproducibility of DCE-MRI derived
AUC (interscan, intraobserver, and
interobserver ICCs > 0.75, P< 0.001)
Wu et al. [28••] NZW Rabbit1 Method development Demonstration of feasibility of simultaneous
VIF and vessel wall imaging with accurate
estimation of pharmacokinetic parameters
(Patlak)
Calcagno et al. [29] NZW Rabbit3 Histological validation Positive correlation (ρ= 0.89, p= 0.016) between
AUC and amount of neovessels in the intima
Calcagno et al. [30•] NZW Rabbit3 Histological validation 3D DCE-MRI (AUC (ρ= 0.45) and Ktrans (Patlak)
(ρ= 0.38)) is able to quantify microvascular
permeability in the entire abdominal aorta
plaque
Chen et al. [31] NZW Rabbitd To study plaque progression DCE-MRI (AUC) is able to quantitatively assess
temporal changes of atherosclerotic plaques
over a period of 3 months
Kim et al. [32] NZW Rabbit3 Validation of a chip for the
development of nanomedicines
Increased AUC for atherosclerotic animals
compared to control animals. Lipid-polymer
hybrid nanoparticle translocation is correlated
with AUC (ρ= 0.79, p< 0.0001)
Lobatto et al. [33] NZW Rabbit3 Evaluation of glucocorticoid
treatment for atherosclerosis
DCE-MRI (AUC) reveals early changes in plaque
microvascular permeability after liposomal
glucocorticoid treatment
Vucic et al. [34] NZW Rabbit3 Evaluation of pioglitazone
treatment for atherosclerosis
DCE-MRI (AUC) can demonstrate the anti-
inflammatory effect of pioglizatone on
atherosclerotic plaques
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Table 1 (continued)
Reference Subjects Main study purpose Main study outcome
Vucic et al. [35] NZW Rabbit3 Evaluation of LXR agonist
R211945 treatment for
atherosclerosis
DCE-MRI (AUC) showed a trend towards a
decreased microvasculature after treatment
with atorvastatin




Ktrans and vp (Patlak) differed significantly
between plaque components (lipid core,
IPH, calcifications, loose matrix, and
fibrous tissue), except between
calcifications and IPH.




Weak, inverse relationship between
inflammation (18F-FDG PET-CT, mean
TBR) and plaque perfusion (DCE-MRI,
Ktrans (extended TK))
Dong et al. [38] Humans (carotid plaque
thickness ≥2 mm)
Evaluation of intensive lipid
therapy in the treatment of
atherosclerosis
Intensive lipid therapy (using atorvastatin,
niacin, and colesevelam) results in a
reduction in Ktrans (Patlak) after one year
Gaens et al. [39] Symptomatic patients
(30–99 % carotid stenosis)
Pharmacokinetic model
comparison
The Patlak model is the most suited
quantitative model for description of
carotid plaque microvasculature
Kerwin et al. [40] CEA Patients Validation against
microvasculature on
histology
Strong correlation (ρ= 0.80, p < 0.001)
between DCE-MRI and histological
measured fractional vascular areas
Kerwin et al. [41] CEA Patients Validation against
microvasculature and
inflammation on histology
Ktrans (Patlak) is a quantitative and non-
invasive marker of plaque inflammation
(ρ= 0.75, p < 0.001) and microvasculature
(ρ= 0.71, p < 0.001)
Kerwin et al. [42] CEA Patients Validation against
microvasculature and
inflammation on histology
Adventitial Ktrans (Patlak) was significantly
correlated with the amount of
microvasculature (ρ= 0.41, p= 0.04) and
macrophages (ρ= 0.49, p = 0.01)
Mani et al. [43] Humans with and without
exposure to particle matter
Risk stratification High exposure to particle matter may be
associated with plaque neovascularization,
measured with DCE-MRI (AUC)




Shorter duration of statin therapy before
occurrence of clinical event is associated
with increased vp (Patlak)
Sun et al. [45•] Symptomatic patients
(ischemic event <6 m)
Correlation between
DCE-MRI (Ktrans)
and presence of IPH
Presence of IPH was associated with an
increase of 28 % of adventitial Ktrans
(Patlak)
Truijman et al. [46] Symptomatic patients
(30–69 % carotid stenosis)
Correlation with 18F-FDG
PET-CT
Weak, positive relationship between
inflammation (18F-FDG PET-CT, TBR)
and plaque perfusion (DCE-MRI, Ktrans
(Patlak))




Correlation between 18F-FDG PET (TBR)
and DCE-MRI (Ktrans, Patlak) measurements
varied with clinical conditions
(symptomatic status)
DCE-MRI dynamic contrast-enhanced MRI, 18 F-FDG 18 fluorine-fluorodeoxyglucose, PET-CT positron emission tomography/computed tomography,
AUC area under the curve, NIRF near-infrared fluorescence, CVD cardiovascular disease, CEA carotid endarterectomy, CHD coronary heart disease,
TBR target-to-background ratio, NZW New Zealand White
a Atherosclerosis was induced by a balloon injury of the aorta in combination with a high cholesterol-enriched diet (1.0 %)
b Pharmacologic triggering was performed to stimulate plaque disruption
c Atherosclerosis was induced by a balloon injury of the aorta in combination with a low cholesterol enriched diet (<1.0 %) combined with palm oil
d Atherosclerosis was induced by a balloon injury of the aorta in combination with a low cholesterol enriched diet (<1.0 %)
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Semi-Quantitative Assessment of the Microvasculature
The microvasculature can be assessed semi-quantitatively
using the area-under-the-curve (AUC) of the (relative) signal
enhancement curve. This requires that start- and end-time
points are selected over which the AUC will be calculated.
Generally, the moment of contrast arrival in the tissue of in-
terest is chosen as the starting point, and the end time point is
chosen empirically. It must be noted that when the end point is
chosen relatively close to the contrast injection, the AUC re-
flects early contrast arrival, whereas a later end point will
cause the AUC to reflect total leakage (and entrapment) of
contrast medium in the plaque tissue.
The main advantage of semi-quantitative analyses is the
relatively easy implementation. However, the information is
limited because there is no direct relationship between the
AUC and (patho)physiological parameters. Although research
in the field of oncology [51] has shown that the AUC reflects
pathophysiology, it does so non-specifically, meaning that one
particular AUC value can indicate a number of biological prop-
erties. Thus, an increased AUC can indicate increased leakage
of the contrast medium from the microvasculature, increased
density of microvessels, increased flow through the microvas-
culature, a decrease in reflux from the extracellular extravascu-
lar space to the microvasculature, or a combination of these.
Therefore, changes or differences in the AUCmay result from a
variety of phenomena so that it may be difficult to attribute
these changes to a single, underlying physiological cause.
Similarly, effects of therapeutic interventions may potentially
be obscured using the AUC. Another drawback of semi-
quantitative analysis is the difficulty of direct comparison of
results between studies because the AUC also depend on set-
tings of the MR system, such as receiver gain.
Validation of Semi-Quantitative DCE-MRI Parameters
Validation of semi-quantitative DCE-MRI was performed
in several balloon injured cholesterol-fed New Zealand
White rabbit studies. It was found that the AUC positively
correlated with microvessel count in the intima of histo-
logical specimens (Pearson’s ρ of 0.89 (p = 0.016) and
0.91 (p= 0.011) for the AUC 2 and 7 min after contrast
injection, respectively) [29]. Furthermore, later research
[27] showed a good interscan and excellent intra- and
inter-observer reproducibility (all ICCs > 0.75, p< 0.01).
Another atherosclerotic rabbit study compared two
three-dimensional (3D) high spatial resolution DCE-MRI
sequences (3D turbo field echo (TFE) with motion-
sensitized-driven equilibrium (MSDE) preparation and a
3D turbo spin echo (TSE) sequence) [30•]. A moderate
Pearson correlation was found between AUC and ex vivo
permeability measurements using Evans Blue (an
albumin-binding dye used for quantification of ex vivo
vascular permeability) near-infrared fluorescence (NIRF)
(ρ= 0.45 for 3D TFE MRI and ρ= 0.39 for 3D TSE MRI).
In addition, a fourfold improvement of temporal resolu-
tion was achieved when using compressed sensing by ret-
rospective undersampling and reconstruction. In another
study, comparison between in vivo (3D DCE-MRI) and
ex vivo (Cy7-labeled near-infrared fluorescence [NIRF])
measures of microvascular permeability in the aortic wall
of atherosclerotic rabbits showed a high degree of corre-
lation between both imaging modalities (r2 = 0.65,
p< 0.0001) [32].
These studies [27, 29, 30•, 32] have demonstrated repro-
ducible representation of plaque microvasculature through
semi-quantitative DCE-MRI parameters.
Fig. 1 MR images (a–c) of a transverse section of the carotid plaque in
the internal carotid artery from a 64-year-oldman. In a, A black blood T1-
weighted turbo spin echo MR image as an anatomical reference. In this
image, the vessel lumen (circle) appears in black. The atherosclerotic
plaque of this patient appears hyperintense compared to the sternocleidoid
muscle (diamond). In b, a three-dimensional T1-weighted fast field-echo
dynamic contrast-enhanced MR image that is acquired 6 min after
contrast injection is shown. In this image, the vessel lumen (circle)
appears bright compared to the atherosclerotic plaque and surrounding
tissues. A ring of enhancement can be observed at the outer part of the
vessel wall (indicated by white arrows), which is attributed to the micro-
vasculature originating from the adventitia. Finally, in c, a parametric
Ktrans map is overlaid on DCE-MRI image shown in b. In this parametric
map, voxel wise determined Ktrans values are color encoded from 0 to
0.2 min−1. Within this overlay, the lipid-rich necrotic core in the center of
the plaque, exhibits low Ktrans values (dark), while the highly
vascularized adventitia (high Ktrans values) at the outer rim (indicated
by the arrows) is clearly visualized (red regions). Circle, internal carotid
artery; star, external carotid artery; diamond, sternocleidoid muscle.
Figure adapted from Truijman et al. [46]
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Quantitative Assessment of the Microvasculature
Pharmacokinetic Modeling
Pharmacokinetic modeling allows the quantification of con-
trast medium distribution over a tissue of interest with the
main advantage of deriving parameters of the in vivo physical
quantities of the amount, flow, and leakiness of the
microvasculature.
A number of quantitative DCE-MRI data analysis models
have been applied in the evaluation of atherosclerotic plaque
microvasculature (Table 2). These models describe the rela-
tionship between the concentration of the (extracellular) con-
trast medium in the blood plasma (Cp) and the extracellular
extravascular space (Ce) according to the two-compartment
model and using the parameters Ktrans, ve, and vp. K
trans, the
transfer constant of contrast medium from plasma to the tissue
compartment, serves as an indicator of blood supply and ves-
sel permeability within the atherosclerotic tissue. The param-
eters ve and vp represent the extravascular extracellular space
and the plasma fractional volume, respectively. A schematic
representation of the physiological meaning of the parameters
is shown in Fig. 2.
The modified/extended Tofts and Kermode (TK) model
[52, 53] is a commonly employed analytical solution for the
two-compartment model [54, 55], estimating all three phar-
macokinetic parameters (Ktrans, ve, and vp). The original TK
model, which was proposed for the study of multiple sclerosis
[56], does not take vascular contribution into account (i.e., vp
is assumed to be negligible). The Patlak model [57] assumes
that reflux, i.e., transfer of contrast medium from the tissue
compartment back to the blood plasma (Ktrans/ve), is negligi-
ble. Recently, an approximation of the modified TKmodel has
been introduced as an intermediate solution between the mod-
ified TK and the Patlak model: the extended graphical model
[23]. This model uses the first-order term of a Taylor series
from the modified TK model to estimate ve.
Vascular Input Function
One essential requirement for quantitative analysis of DCE-
MRI data is knowledge of the contrast medium concentration
in the blood vessel over time, commonly, referred to as the
arterial or vascular input function (AIF/VIF). Two main fea-
tures of the VIF are a high relative peak concentration and a
short bolus passage compared to other tissues. Accurate deter-
mination of the VIF requires a relatively high temporal reso-
lution, which usually results in compromise with regard to the
spatial resolution that can be achieved.
Two strategies can be employed for the determination of
VIF. The first strategy is based on the assumption that VIF is
similar in all subjects and a generalized population-averaged
VIF, obtained from literature or determined in a cohort is used
[24, 39, 46, 50]. An advantage of this method is that data
acquisition and analysis requirements are simplified [49].
The second strategy involves measurement of patient-
specific function, giving the potential advantage of accounting
for variations between subjects [58]. Previous research in on-
cology found comparable results using either method, and the
use of population-averaged vascular input functions resulted
in increased [50] or comparable [59] reproducibility. In clini-
cal studies of atherosclerotic plaque microvasculature, a
Table 2 Overview of quantitative DCE-MRI models used in the anal-
ysis of atherosclerosis. Quantitative pharmacokinetic models used for the
analysis of atherosclerosis based on the two-compartment model. The
modified/extended Tofts and Kermode model is the analytical solution
for the two-compartment model. The extended graphical model is based
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generalized VIF is the most commonly chosen method, prob-
ably because of the required spatial resolution for accurate
imaging of atherosclerotic plaque in the carotid artery. The
generalized VIF can be obtained from a separate study cohort
where acquisition is performed with a higher temporal resolu-
tion and a lower spatial resolution.
The VIF with MRI can be calculated by two different
methods. The first method uses the magnitude of the ac-
quired MR signal and is based on conversion of the relative
signal enhancement to contrast medium concentration
using the Ernst equation [60]. For this conversion, blood
relaxation and contrast medium relaxivity rates are taken
into account. A second method based on MR signal phase
has been developed more recently [61, 62]. First used in
brain perfusion studies with dynamic susceptibility MRI
[63], the technique is increasingly used in DCE-MRI [24,
64]. Efforts have been made to compare the magnitude-
and phase-based techniques [24, 59, 65–67], showing a
strong potential for the phase-based technique, allowing
accurate VIF quantification. In a DCE-MRI study of 17
symptomatic patients with a mild to severe carotid steno-
sis, it was found that the magnitude-based VIF resulted in a
strong underestimation of lumen contrast medium concen-
tration as compared to the phase-based VIF [24].
Simulations and phantom experiments showed that this
underestimation is caused by local blood flow velocity,
which leads to saturation of the magnitude MR signal
caused by the shortened T1 relaxation time in the presence
of contrast medium. Analysis of Ktrans values using
population-averaged input functions showed a strong
positive correlation between the two methods, although
absolute values significantly differed.
Validation of Quantitative DCE-MRI Parameters
Histological validation of carotid plaque DCE-MRI has been
carried out using reference specimens from patients after ca-
rotid endarterectomy (CEA). However, the drawback of all
such validation studies is that these are performed in patients
scheduled for CEA. Large randomized trials have shown that
symptomatic patients with severe ipsilateral stenosis benefit
the most from CEA [68]. This population is more likely to
have developed advanced atherosclerotic plaques. In addition,
the surgeon removes the intima and part of the media of the
vessel wall and the adventitia, from which microvasculature
originates [6], is missing in the CEA specimen. An additional
limitation of the comparison of in vivo MRI with histological
measurements as a reference standard is the comparison of a
thin histological slice to thicker MR imaging slice (typically
2 mm). Due to the heterogeneous nature of atherosclerotic
lesions, this may result in partial volume effects.
Despite these drawbacks, a strong and positive correlation
between fractional blood volume derived from in vivo MRI
and post-surgical histology (0.80, p<0.001) was found in 16
CEA patients [40]. In addition, a significant Pearson correla-
tion was reported between the transfer constants Ktrans calcu-
lated from in vivo DCE-MRI with postsurgical histologic
measurements of the microvessel area (ρ= 0.71, p< 0.001
for the entire vessel wall Ktrans and ρ=0.41, p<0.04 for ad-
ventitial Ktrans). Additionally, an association between Ktrans
and other postsurgical histological parameters was reported,
i.e., macrophage density (ρ=0.75, p<0.001 for the vessel
wall Ktrans and ρ=0.49, p<0.01 for adventitial Ktrans), loose
matrix area (ρ=0.50, p=0.01, for vessel wall Ktrans) [41, 42].
It was also shown that Ktrans and vp differed significantly
between different plaque components (lipid core, IPH, calci-
fications, loose matrix, and fibrous tissue), except between
calcifications and IPH [36].
Reproducibility, fit error, parameter uncertainty, and corre-
lation with histology of carotid plaque DCE-MRI were com-
pared for four pharmacokinetic models in patients withmild to
severe carotid stenosis [39]. Analysis of 43 patients showed
the highest relative fit error for the Tofts model, while the
other three models did not differ in this regard. The Patlak
model had a significant lower parameter uncertainty for
Ktrans as compared to the other models. Reproducibility was
studied in 16 asymptomatic patients with 30–69 % carotid
stenosis who underwent imaging twice with several (4.3
±2.8) days between the two examinations. Results showed a
good reproducibility for all considered pharmacokinetic
models (ICC>0.6, p<0.05) for Ktrans and significant scan-
rescan ICCs for ve (Tofts) and vp (Patlak). Correlation with
histologic findings in 13 CEA patients showed significant
Fig. 2 Schematic representation of parameters used in pharmacokinetic
models for analysis of atherosclerotic plaque microvasculature. Within a
single region of interest or voxel, the fractional blood volume
(microvasculature) is represented by vp, while the fraction of the extra-
cellular extravascular space is represented by ve. Contrast medium trans-
fer rate from the microvasculature to the extracellular extravascular space
is given by Ktrans; the reflux is described by Ktrans/ve. In most DCE-MRI
studies, an extracellular contrast medium with a low molecular weight is
used. For quantitative data analysis, therefore, a two-compartment model
can be used (i.e., vascular and extracellular extravascular compartments).
Based on this general concept and setting various assumptions, several
different quantitative models can be derived. An overview of these
models is presented in Table 2
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positive Pearson’s correlation (ρ=0.7; p<0.01) with the entire
vessel wall microvasculature for all models, with the excep-
tion of the Tofts model. It was concluded that the Patlak model
was the most suited of these four models for pharmacokinetic
modeling of the microvasculature in atherosclerotic plaques
[39]. Another study [23], however, found favorable results for
the extended graphical model for simulated and selected in
vivo data of carotid plaques with good to excellent image
quality. Their results showed that a compromise between
noise and bias sensitivity has to be made when choosing be-
tween the Patlak and extended graphical models.
The scan-rescan reproducibility of DCE-MRI was also
investigated in a multi-center study [18] of 35 subjects
with established cardiovascular disease recruited from 15
hospitals. Results showed a moderate reproducibility for
Ktrans with a coefficient of variation of 25 %. The rela-
tively high dropout rate within the study (31.4 %) sug-
gested a need for intensive operator training, an optimized
imaging protocol, and quality control.
The dependence of model parameters on contrast medium
was investigated in a study comparing two extracellular con-
trast media [21]. Quantitative analysis of DCE-MR images
demonstrated a lower Ktrans when using gadobenate
dimeglumine (0.0846 min−1) as compared to gadodiamide
(0.101 min−1, p<0.01), while no difference in vp was found.
In order to facilitate direct comparison of quantitative DCE-
MRI parameters between- or in longitudinal studies, the use of
the same contrast medium is recommended.
Taken together, despite the recognized limitations, the
above studies demonstrate the suitability of quantitative
DCE-MRI parameters for reproducibly determining plaque
microvasculature characteristics.
Overview of DCE MRI Studies to Study Plaque
Microvasculature
Association Between DCE-MRI Parameters and Other
Plaque Features
Many plaque characteristics and pathological features contrib-
ute to the risk for disruption and thrombosis, and studies have
been designed to investigate possible associations between
plaque microvasculature and other plaque features. In recent
years, several studies [31, 37, 45•, 46, 47•] were carried out to
investigate associations between DCE-MRI parameters,
plaque inflammation, and the presence of IPH. In a preclinical
study of cholesterol-fed balloon-injured atherosclerotic rabbits
[31], a positive Pearson correlation (ρ=0.70, p=0.01) was
found between DCE-MRI derived parameters and histologi-
cally determined plaque macrophage content.
The relationship between DCE-MRI parameters and plaque
inflammation using 18fluorine-fluorodeoxyglucose (18F-FDG)
PET-computed tomography (CT) has been investigated in sev-
eral clinical studies [37, 46, 47•]. One study of 49 symptomatic
patients with mild to moderate carotid stenosis [46] reported a
weak positive correlation (Spearman ρ=0.30, p=0.035) be-
tween plaque inflammation (mean Target-to-Background Ratio
(TBR) on 18F-FDG PET-CT) and plaque perfusion (mean
Ktrans). Another study of 33 patients [37] with coronary heart
disease (CHD) or CHD risk equivalent and a carotid plaque with
TBR≥1.6 on 18F-FDG PET-CT [69] found a significant inverse
relationship between plaque perfusion (Ktrans) and plaque in-
flammation on 18F-FDG PET-CT of ρ=-0.24 (p<0.05). A sub-
sequent study of 41 patients with carotid plaque [47•] found that
correlations depend on the clinical condition of patients. Overall,
a weak,marginal non-significant correlation (Spearman ρ=0.22,
p=0.068) was found for all, both symptomatic and asymptom-
atic, carotid plaques. A significant difference in Spearman cor-
relation coefficients between TBR and Ktrans was found when
grouped according to the symptomatic and asymptomatic carot-
id plaques (p=0.033): a significant correlation (Spearman
ρ=0.59, p=0.006) was found for symptomatic carotid plaques,
not seen for asymptomatic plaques (Spearman ρ = 0.07,
p=0.625). Also, an inverse relationship was found between
the time since the last neurological event and both parameters
(Spearman ρ=−0.94 for TBR and Spearman ρ=−0.69 for
Ktrans). These results point towards a complex interplay between
inflammation and microvasculature in atherosclerotic plaques
that is difficult to capture in clinical imaging.
The link between plaque microvasculature and the specific
feature of intraplaque hemorrhage (IPH) has been investigated
in symptomatic patients with moderate to severe carotid ste-
nosis [45•]. The presence of IPH on MP-RAGE MR images
was associated with a significant increase in Ktrans of 28 %
(p<0.001) in the adventitial layer of the vessel wall as com-
pared to arteries where IPH was absent (p<0.001). A multi-
variate analysis adjusting for symptomatic status, degree of
stenosis, and male sex showed that the increased Ktrans in
arteries with IPH remained significant (p=0.018).
These studies show the potential of DCE-MRI as a tool to
gain more insight in relation between plaquemicrovasculature
and other features of vulnerable atherosclerotic lesions.
Monitoring Longitudinal Changes in Plaque
Microvasculature
DCE-MRI can be used to follow progression of atherosclerot-
ic plaques, as illustrated by a preclinical study [31] of
cholesterol-fed atherosclerotic rabbits. One group of rabbits
was imaged 3 months after balloon denudation, immediately
followed by euthanasia, and a second group at 3 and 6 months
after balloon denudation. From 3 to 6 months after balloon
denudation, an increase of 40 % in Ktrans was found measured
by DCE-MRI, suggesting that DCE-MRI can be used to in-
vestigate plaque microvasculature development.
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Differences Between Different Animal Groups
and Human Subjects with a Different Cardiovascular
Risk Profile
In a recent rabbit study [32], investigating the development of a
microfluidic chip for potential future nanomedicines an in-
creased AUC within the abdominal aorta for atherosclerotic
animals as compared to control animals was reported. In an-
other study of cholesterol-fed rabbits with induced plaque dis-
ruption [26], it was shown that ruptured plaques can be distin-
guished from stable plaques by spatial-temporal texture-based
features of DCE-MRI. The effect of exposure to high particu-
late airborne matter on atherosclerosis was investigated in
BGround Zero^ workers in New York City with high and low
exposure to particulate matter using DCE-MRI [43]. Subjects
with high exposure had a significantly higher AUC in the ca-
rotid artery (+41%) as compared to subjects with low exposure
(p=0.016), indicating increased changes of the plaque micro-
vasculature. These changes may range from increased leakage
of contrast medium from the microvasculature, increased
microvessel density, increased flow through the microvascula-
ture, decreased reflux from the extracellular extravascular space
to the microvasculature, or a combination. The authors of the
study concluded that a high exposure to particulate matter may
lead to increased plaque microvasculature, potentially indicat-
ing an increased risk for further development of atherosclerosis.
Evaluation of Therapies
DCE-MRI enables the study of plaquemicrovasculature chang-
es over time, making it useful in animal and patient drug effect
studies. Changes in microvasculature may reflect changes in
phenotype and/or vulnerability of the atherosclerotic plaque.
DCE-MRI has been employed in several preclinical
cholesterol-fed balloon-injured atherosclerotic rabbit studies
investigating potential anti-inflammatory treatments of athero-
sclerosis [33–35]. The effect of liposome-encapsulated pred-
nisolone phosphate (L-PLP) on atherosclerosis was investigat-
ed using MR imaging before treatment, immediately after in-
jection with L-PLP, and over time [33]. A reduction of the
plaque AUC was found from pre-treatment to 2 days post-
treatment, revealing early changes in microvascular perme-
ability after treatment. In a further study, the anti-
inflammatory effects of pioglitazone on atherosclerotic
plaques were investigated [34]. DCE-MRI analysis showed
a 22 % decrease in AUC for the treatment group (p<0.01)
over the study time period of 3 months, while no decrease in
plaque enhancement was found for the control group. No
changes in vessel wall area measurements were found during
the study period for either animal group. A third study [35]
evaluated the anti-inflammatory effects of a liver X receptor
(LXR) agonist which induces reversal cholesterol transport, as
compared to atorvastatin. The 3-month treatment with LXR
did not lead to changes of the microvasculature, whereas treat-
ment with atorvastatin caused a trend towards a decrease in
microvasculature (p=0.06). No differences in vessel wall area
measurements were found. Combined, these studies have
shown the potential of DCE-MRI to study changes of the
plaque microvasculature in the evaluation of potential new
therapies. A limitation of these studies, however, is that the
rabbits did not exhibit plaque disruption with luminal throm-
bosis, the clinical endpoint of high risk plaques.
DCE-MRI has been used to study the effect of intensive
lipid therapy over a period of 12 months [38] in patients with
coronary artery disease or carotid disease and increased levels
(≥120 mg/dl) of apolipoprotein B from the Carotid Plaque
Composition study [70]. Results of the study show that 12-
month therapy leads to a significant reduction of 21 % in
Ktrans. This is consistent with the hypothesis that intensive lipid
therapy results in a reduction of the extent and permeability of
atherosclerotic plaque microvasculature. A study with 98 sub-
jects with established cardiovascular disease [44••] selected
from the AIM-HIGH trial [19] found an inverse association
between vp (plaque microvasculature fraction) and the duration
of statin therapy. Statins are commonly used to lower lipid
levels and also possess anti-inflammatory properties [71].
These results suggest that a relationship exists between duration
of statin therapy and plaque microvasculature, which could
reflect a decreased level of vascular inflammation.
The above studies on DCE-MRI of plaque microvascula-
ture have measured differences between treatment groups or
subjects with increased cardiovascular risk and shown that
DCE-MRI can be employed effectively as an evaluation tool.
Challenges and Future Perspectives in DCE-MRI
of Atherosclerosis
To further advance DCE-MRI for wider use in clinical prac-
tice, uniform acquisition and analysis methods need to be
agreed upon. Previous studies have shown that DCE-MRI-
derived parameters are influenced by the contrast medium,
vascular input function, and which pharmacokinetic model
is used, making direct cross-study comparisons difficult. Use
of a standard imaging and data analysis protocol is essential,
therefore, for longitudinal studies of plaque microvasculature.
A very important clinical precaution is use of a stable
Gadolinium-based contrast medium [72] using low dosages
to minimize the risks for nephrogenic systemic fibrosis and
deposition of the contrast medium in the brain.
The recent introduction of interleaved acquisition methods
[28••], providing both bright and black blood images, may be
an important step toward the determination of an individual-
ized vascular input function. In addition, 3D acquisition tech-
niques [30•] may provide increased spatial accuracy as com-
pared to currently employed 2D techniques, although at the
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expense of temporal resolution. Currently, these 3D acquisi-
tion techniques have only been explored in preclinical rabbit
studies; their potential in clinical studies remains to be
investigated.
All clinical DCE-MRI studies, to date, have been per-
formed at 1.5 and 3.0 T. The potential of carotid MRI at
7.0 T has already been explored [73, 74], and results show a
potential increase in signal-to-noise ratio (SNR) due to the
increased field strength. However, the increase in SNR may
be diminished by increased relaxivity of the contrast medium,
which may also require longer scan times. The potentially
increased SNR at 7.0 T would allow increased spatial and/or
temporal resolution, but these studies also demonstrate that
further technical developments are required to enable com-
plete plaque characterization.
Associations between plaque microvasculature
(measured using DCE-MRI) and plaque inflammation
(measured by 18F-FDG uptake or macrophage content)
remain an important area to be studied further since
varying results have been reported to date. The reported
association between and plaque microvasculature and
intraplaque hemorrhage could be studied longitudinally.
The recent introduction of hybrid PET-MRI systems
provides excellent opportunities for further investigation
of the relationships between these processes using a
single imaging system. Recent research [75–79] has al-
ready shown the potential of hybrid PET-MR systems
for the imaging of atherosclerosis. However, the addi-
tional value of DCE-MRI in PET/MR imaging is yet to
be explored.
The predictive value of DCE-MRI for plaque progression
or development of vulnerable plaque features is of great inter-
est and remains to be determined; in addition, its predictive
value for cerebrovascular ischemic events needs to be inves-
tigated in a prospective clinical trial.
Applications of DCE-MRI can be extended beyond the
carotid artery to other (human) vascular territories, such as
the microvasculature in the aortic wall of abdominal aortic
aneurysms [80, 81]. These measurements were reproducible
with a high technical success rate, and the Patlak model was
the most suited pharmacokinetic model. Future studies are
warranted to investigate the predictive potential of
DCE-MRI derived parameters for abdominal aortic an-
eurysm rupture risk.
Conclusion
Over the past decade, DCE-MRI has developed from a novel
imaging tool to a useful non-invasive research tool used in
animal and patient studies of plaque microvasculature. DCE-
MRI has been used to investigate the relationship between
plaque microvasculature and other plaque features such as
inflammation and intraplaque hemorrhage, for assessing
effectiveness of therapeutic interventions, and in the
evaluation of plaque microvasculature changes over time
and between groups with increased cardiovascular risks.
Future studies could apply DCE-MRI to elucidate
plaque development mechanisms, specifically the inter-
play between inflammation, increased microvasculature,
and intraplaque hemorrhage. Also of great interest is the
potential predictive value of plaque microvasculature
DCE-MRI for plaque progression and future cerebrovas-
cular ischemic events (such as stroke).
Search Strategy
The studies discussed in the present review have been identi-
fied through a database search in MEDLINE in December
2015 using the fol lowing search terms: Bcarot id
atherosclerosis^/Batherosclerosis^/Batherosclerotic plaque^/
Batherosclerotic plaques^/Bplaque^ AND Bhuman^/Brabbit^
AND BDCE-MRI^/Bdynamic contrast enhanced MRI^/
BMRI^/Bdynamic contrast enhanced magnetic resonance
imaging^/Bmagnetic resonance imaging^ AND Bneovessels^/
Bneovascularization^/Bneovasculature^/Bvasa vasorum^/
Bmicrovasculature^/Binflammation^. Resulting abstracts and
articles were screened and references checked for possible ad-
ditional studies.
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